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Purpose. To describe the acquisition, persistence, and clearance of HPV infection in women with CIN 2 followed up for 12 months.
Methods. Thirty-seven women with CIN 2 biopsy, who have proven referral to cervical smear showing low-grade squamous
intraepithelial lesions or atypical squamous cells of undetermined significance and tested for HPV, were followed up for one year
with cervical smear, colposcopy, and HPV test every three months. HPV DNA was detected by the polymerase chain reaction and
genotyping by reverse line blot hybridization assay. Results. CIN 2 regression rate was 49% (18/37), persistence as CIN 1 or CIN 2
was 22% (8/37), and progression to CIN 3 was 29% (11/37). Multiple HPV types were observed at admission in 41% (15/37) of cases.
HPV 16 was detected at admission in 58% (11/19) of the cases that persisted/progressed and in 39% (7/18) of the cases that regressed.
HPV 16 was considered possibly causal in 67% (10/15) of the cases that persisted or progressed and in 10% (1/10) of the cases that
regressed (𝑃 = 0.01). Conclusion. Multiple HPV infections were frequently detected among women with CIN 2 at admission and
during the followup. The CIN 2 associated with HPV 16 was more likely to persist or to progress to CIN 3.
1. Introduction
Cervical intraepithelial neoplasia (CIN) and cervical cancer
derive from cellular transformations of the cervix epithelium
after HPV infection. High-risk HPV (HR-HPV) persistent
infections represent a necessary cause of cervical cancer, but
not sufficient [1]. Additional conditions and events are requi-
red for the neoplastic transformation.
Firstly, it was thought that cervical squamous cell carci-
nomas (SCC) would always evolve from HPV infected nor-
mal cervical epithelium via a continuum, long-lasting con-
secutive CIN 1, CIN 2, and CIN 3 lesions [1]. However, it has
been shown that clinically relevant CIN 2 or CIN 3 may be
induced within 2-3 years following HPV high-risk infection,
and another 10–12 years may pass until invasive cervical
carcinoma would develop [2]. Most CIN 1 lesions that are
associated withHR-HPV, and someCIN 2 lesions, should not
be considered as true precursor stages of cervical cancer but
rather the cytopathic effect of a productive viral infection [3].
Moreover, CIN 1 regression rate is high [4], as is the regression
rate of CIN 2 [5–7], and both display viral expression
patterns suggestive of productive viral infections. In contrast,
some CIN 2 lesions and CIN 3 lesions show different viral
gene expressions, leading to atypical proliferation and cell
transformation. The development of CIN 3 arises in women
who cannot resolve the HPV infection, and therefore the
infections can persist for years or decades following initial
exposure [8].
CIN 2 thus is a borderline lesion, can show clinical beha-
vior similar to CIN 1 or to CIN 3, and occurs frequently
in young women [6]. The 2012 Updated Consensus Guide-
lines of the American Society for Colposcopy and Cervical
2 Obstetrics and Gynecology International
Pathology (ASCCP) [9] recommend that when a histological
diagnosis of CIN 2 is specified for a young woman, observa-
tion is preferred, provided colposcopy is adequate.
The pattern of HPV infection and reinfection in women
and the outcome of CIN 2 are not well known. A better dis-
crimination of CIN 2 that trends to progression or regression
could help in choosing the best clinical management. This
study therefore aimed to describe the acquisition, persistence,
and clearance of HPV infection in women with CIN 2
confirmed by biopsy followed for 12 months under expectant
management.
2. Materials and Methods
2.1. Study Design and Ethical Methods. This cohort study was
a part of a research for evaluating expectant management of
women with CIN 1 and CIN 2, carried out between January
2007 and December 2009 at the State University of Campinas
(UNICAMP), Campinas SP, Brazil. It was approved by the
Institutional Review Board of the Faculty ofMedical Sciences
of UNICAMP.
2.2. Selection and Followup of the Women Studied. Women
aged 18 to 46 years old were considered eligible for the study
if they fulfilled the following criteria: (1) referral cervical
smear showing atypical squamous cells of undetermined
significance (ASCUS) or low-grade squamous intraepithe-
lial lesion (LSIL); (2) biopsy showing CIN 2 reviewed by
senior pathologist who was unaware of the DNA HPV test
results [10]; (3) lesion completely visualized by colposcopy
and squamocolumnar junction totally visible; (4) not being
pregnant; (5) showing no evidence of any immunodeficiency
diseases; (6) no history of previous invasive neoplasia; (7)
HPV test result. The selection of patients was fully described
in a previous publication (5). Fifty women consecutively
fulfilled these criteria, agreed to participate in the study, and
signed the informed consent.
The planned followup was visits every three months
during one year with cervical smear, colposcopy, and sample
collection forHPVdetection.The colposcopic image showing
a worsening of the lesionmargem, color, and vascular pattern
was submitted to biopsy. When the biopsy revealed CIN 2
or a less severe diagnosis, the woman was maintained in
the follow-up plan. When the biopsy revealed CIN 3, imme-
diate treatment by excision of the lesion was performed.
At one year of followup, all the women who still showed
cytological or colposcopy abnormalities were submitted to
complete evaluation, and they were treated according to the
final diagnosis. No ablative procedures were carried out.
During followup, 13 women were discontinued due to
the following: five women diagnosed with persistence in the
intermediate visit did not show up for the final visit; one
woman tested positive for HIV; one woman missed three
consecutive visits; one woman became pregnant; five women
were without at least one HPV test during followup. After 12-
month followup, 37 women had final diagnosis established.
2.3. Outcome of CIN 2 Followup. The final outcome of CIN
2 was classified as progression, persistence, or regression,
according to the following criteria.
(i) Progression: biopsy showing CIN 3 detected at any
time during the followup. No lesion worse than CIN
3 was revealed.
(ii) Persistence: biopsy showing CIN 1 or CIN 2 at twelve-
month followup.
(iii) Regression: concomitant negative cervical smear and
negative colposcopy or negative biopsy observed at
any time during the followup and confirmed at
twelve-month followup. If the patient had a HLSIL
cervical smear and negative biopsy, it was not con-
sidered regression and the patient was submitted to
excisional treatment.
2.4. Possible Causal HPV Type. The HPV type possibly
associated with the CIN 2 lesion was considered the possibly
causal type. For the CIN 2 lesions that regressed, possibly
causal HPV was considered when HPV type was detected at
admission and persisted up to the follow-up visit immediately
before the regression. If the lesion persisted, either as CIN 1 or
CIN 2, possibly causal HPV was considered when detected at
admission and during the follow-up visits. Among the cases
that progressed, possibly causal HPV was considered when
detected at admission and at least until the follow-up visit
when progression was detected. The possibly causal HPV
type was considered undefined if the test was negative at
admission or if it was not possible to associate the HPV type
with the CIN 2 lesion as described previously.
2.5. Sample Processing and DNA Extraction. Aliquots of
200𝜇L of Universal Collection Medium UCM (QIAGEN
Sample and Assay Technologies, QIAGEN Biotechnology
Brazil Ltda) were taken for polymerase chain reaction (PCR)
testing and were centrifuged for 10 minutes at 13,000 g. The
supernatants were immediately removed, and split cellular
pellets were stored at −80∘C before nucleic acid extraction
and HPV detection. The cellular pellets were resuspended in
200𝜇L of digestion solution (1mMTris, 200mg of proteinase
K/mL, 0.5% sodium dodecyl sulfate) and digested at 55∘C for
2 hours. The digestion was followed by 5-minute incubation
at 95∘C to inactivate the proteinase K. Nucleic acids were
purified by phenolchloroform extraction followed by ethanol
precipitation.The DNA pellet was dried and was dissolved in
100 𝜇L of TE. Nucleic acids were stored at −80∘C before HPV
detection.
2.6. HPV Genotyping. HPV amplification and genotyping
(HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 55, 56, 58, 68,
6, 11, 40, 42, 53, 54, 57, and 66) were performed by the
Roche Linear Array (LA) HPV genotyping test, according to
manufacturer’s instructions.
2.7. Data Analysis. Tables were constructed showing the
HPV type at admission and for every three-month followup,
grouped according to the clinical outcome. The association
between two categorical variables was tested using Fisher’s
Exact Test. The cases with undefined HPV possibly causal
type were not considered for the analysis.
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Table 1: Distribution of HPV types at admission and every three months of followup according to clinical outcome of women with CIN 2.
Clinical outcome Admission Follow-up visit (month) Possibly causal HPV
3rd 6th 9th 12th
Regression at 3rd 71 71, 58 Na Neg 16 Undefined
Regression at 6th
16, 58 16 16 16 Na 58
51 51 Neg Neg Neg 51
26 Na Neg Na 16 26
39, 52, 54, 56, 68 39, 52, 68 52, 51 58 Na 39
16 16 16 16 16 Undefined
31 31 31 31 Neg Undefined
Neg Neg Neg Neg 16 Undefined
16, 56, 66 56, 33 Na 33 Na 56
Neg 16 58 Neg Na Undefined
31 Na 61 Na Na Undefined
Regression at 9th
33 33, 16, 58 33 Neg Neg 33
16, 67 Na 67 Neg 16 67
16 16, 39 Neg Neg Neg 16
6, 16, 33 33 Neg Neg Neg 33
39, 51, 53, 56 Na 39, 51 53, 18 39, 59 51
Regression at 12th Neg Na Neg Na 16, 58, 59 Undefined
16 16 Na Na 16 Undefined
Persistence as CIN 1
16 16 Na 16, 61, 81 16, 61, 81 16
Neg Neg 53 53 53, 16, 42 Undefined
16 16 16 Neg Na Undefined
81 51 81 16 Na Undefined
Persistence as CIN 2
33 Na Na Na 33 33
16, 58 16, 58 16, 58 16, 58 16, 58 16 or 58
16, 58 16, 58 16, 58 16, 58 Na 16 or 58
35, 58, 73 Neg 35, 58, 62 35, 58, 16 Na 35 or 58
Progression at 6th
16 16 16 16 Na 16
16 16 16 16, 66 16, 66 16
16, 33, 68 16, 33, 68 16, 33 16, 33 16, 33, 68 16 or 33
Progression at 9th 16, 68, 84 16, 84, 42, 58 16, 68, 58 16, 68, 58 16, 18 16
Progression at 12th
39 39 39 39 39 39
16, 51, 52, 53 16, 52, 45, 84 16, 52, 84 16, 52, 58 16, 52 16 or 52
16, 52 Na Na 16, 52 16, 52 16 or 52
52, 82 52, 82 52 Na 52 52
6 6, 39 39 Na Na Undefined
31 31 31 Na Na 31
16, 56 16, 56, 73 16, 56, 73 Na Na 16 or 56
New HPV types detected during followup are underlined.
3. Results
Table 1 shows the HPV detection at admission and every
three-month follow-up visit. Women were grouped accord-
ing to CIN 2 clinical outcome. Among the 37 women, 49%
(18/37) regressed, 22% (8/37) persisted as CIN 1 or CIN 2,
and 29% (11/37) progressed to CIN 3. There was no case of
progression to invasive carcinoma detected during the study.
At admission, 41% (15/37) had multiple HPV type detected
and 11% (4/37) had negative HPV test. During followup, 54%
(20/37) of women showed one or more of the newHPV types
detected, resulting in eight more women with multiple HPV
type detected.
Eighteen cases of CIN 2 regressed, of which 39% (7/18)
had HPV 16 detected at admission, 16% (3/18) had HPV 56,
and 16% (3/18) were HPV negative at admission. There were
33% (6/18) of the cases with multiple HPV types detected at
admission and during followup 61% (11/18) presented new
HPV type detected, one case with three new HPV types
and five cases with two new HPV types. The HPV test was
negative at admission or at least at one visit during followup
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Table 2: Association between HPV 16 at admission and as possibly
causal type and clinical outcome of CIN 2 during 12 months of
followup.
HPV 16 Progression/persistence Regression 𝑃 value
𝑛 % 𝑛 %
At admission
Yes 11 58 7 39
No 8 42 11 61
Total 19 100 18 100 𝑃 = 0.20
Possibly causal
Yes 10 67 1 10
No 5 33 9 90
Total 151 100 102 100 𝑃 = 0.01
1Four cases with undefined causal HPV.
2Eight cases with undefined causal HPV.
in 61% (11/18) of cases. The HPV 16 was considered possibly
causal in 6% (1/18) of cases.
Eight cases persisted, four as CIN 1, and four as CIN 2. At
admission, HPV 16was detected in 50% (4/8) of the cases that
persisted, HPV 58 in 38% (3/8), and HPV test was negative
in one case. Multiple HPV types were detected in 38% (3/8)
of the cases at admission and new HPV types were detected
in 50% (4/8). HPV 16 was considered possibly causal in 38%
(3/8) of cases and HPV 58 in 38% (3/8).
Eleven cases (29%) progressed to CIN 3 up to twelve-
month followup. HPV 16 was detected at admission in 64%
(7/11) of the cases, HPV 52 in 27% (3/11), and HPV 68 in
18% (2/11). Multiple HPV types were detected at admission
in 54% (6/11) of cases and newHPV type was detected during
followup in 45% (5/11). Among the cases that progressed there
was no negative HPV test. HPV 16 was considered possibly
causal type in 64% (7/11) of cases.
Table 2 shows the association of HPV 16 with the CIN 2
clinical outcome. Cases that persisted as CIN 1 and CIN 2
were grouped together with the cases that progressed to CIN
3. HPV 16 was detected at admission in 58% (11/19) of the
cases that persisted or progressed and in 39% (7/18) of the
cases that regressed, but this difference was not statistically
significant (𝑃 = 0.20). HPV 16was considered possibly causal
in 67% (10/15) of the cases that progressed or persisted and
in 10% (1/10) of those that regressed, and the difference was
statistically significant (𝑃 = 0.01). The cases with undefined
HPV possibly causal type were not considered for the latter
analysis.
4. Discussion
According to this cohort study, multiple HPV infections were
frequently detected in women with CIN 2, as new HPV types
were also frequently detected during twelve-month followup.
TheCIN2 lesions associatedwithHPV 16weremore frequent
among those lesions that progressed to CIN 3.
Cuschieri et al. [11] showed that multiple high-risk HPV
infections were prevalent in young women, in high and low-
grade cervical intraepithelial neoplasia, reflecting common
sexual transmission of multiple high-risk HPV. Sometimes
the lesion became HPV negative and at the next visit new
infections were acquired. In this scenario, most of the HPV
infections are probably productive, as pointed by Snijders et
al. [1], that is, transitory infections, not inducing transforma-
tion process in the host cell.
Castle et al. [12] found that the presence of HPV 16 was
positively associated with CIN 3 and they reported that CIN
2 caused by HPV 16 may be more likely to progress than CIN
2 caused by other high-risk HPV types [13]. Wentzensen et
al. [14] also showed that CIN 2 related to HPV 16 was more
likely to persist. The absolute risk of precancer diagnosis can
approach 40% after 3–5 years of persistent HPV 16 infection
[15]. Kjær et al. [16], in a population study, found that HPV
16 persistent infection was associated with high absolute risk
for progression to high-grade cervical lesions.
HPV infection can be considered productive when the
expression of viral gene products remains regulated, not
leading to significant host cell changes. Transformation infec-
tions arise where the productive infection cannot be properly
supported due to increased activity of viral protein E6 and
E7, which leads to genomic instability in the infected cell,
accumulation of oncogene mutations, further loss of cell-
growth control, and ultimately precancer lesions and cancer
[8, 17].
There was no negative HPV test in those cases that pro-
gressed, regardless of the HPV type. Among the eight cases
that persisted, three cases presented negative HPV during
followup, but in two cases the lesion persisted as CIN 1.
Among the 18 cases that regressed, 11 presented negative
HPV during followup, indicating transient infections. Only
4 out of 37 cases were HPV negative at admission, which
could be a false negative or a true negative test, but none
progressed.
The regression rate found is not different from the repo-
rted regression rate of CIN 2 in adult women, which ranges
from 15 to 55% regression over 4–6 years of followup [13, 18].
Moscicki et al. reported CIN 2 regression rate of almost
70% among adolescents and young women and progression
rate of 15% at three years [7]. This greater regression rate
might be due to the younger age of the women studied (13
to 24 years old), which could reflect a shorter time of HPV
persistent infection, and to the longer followup of three years.
In the present study, the women’s age was not used to select
the population, the followup was twelve months, and the
progression rate was similar to others that showed greater
risk of CIN 2 progressionwhen the lesionwas associated with
HPV 16 infection [1, 14].
This study has limitations due to small sample subject.
The inclusion criteria were women with cervical smear refer-
ral showing ASCUS or LSIL, CIN 2 proven biopsy, and HPV
test at admission and at least at one follow-up visit, which
limited the number of selected women. Besides, multiple
HPV infections were frequent in these women and, therefore,
the indication of possibly casual HPV type for the CIN 2 was
not always obvious. Despite the lack of reproducibility of CIN
2, the HPV types did not differ significantly between CIN 1,
CIN 2, and CIN 3 [11]. False negative results with colposcopy
and guided biopsy were expected, but this effect is minimized
using cytology as cotesting.
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For clinical practice, the findings of this study suggest that
the HR-HPV testing would have limited utility to indicate
those women with greater risk of CIN 2 progression since the
rate of HR-HPV positive was high among women with CIN
2 regression. Nevertheless, expectant management, which
may be proposed for young women, should be considered
cautiously when HPV 16 infection is detected. In conclusion,
infections with multiple HPV types were frequently detected
at admission and follow-up visits as well as infections with
new HPV types during followup. CIN 2 lesions with HPV 16
alone or in combination with other HR-HPV types are more
prone to progression to CIN 3.
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